MPI INDIUM DTPA IN 111 Drug Patent Profile
✉ Email this page to a colleague
When do Mpi Indium Dtpa In 111 patents expire, and what generic alternatives are available?
Mpi Indium Dtpa In 111 is a drug marketed by Ge Healthcare and is included in one NDA.
The generic ingredient in MPI INDIUM DTPA IN 111 is indium in-111 pentetate disodium. There are twenty-four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the indium in-111 pentetate disodium profile page.
Summary for MPI INDIUM DTPA IN 111
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Clinical Trials: | 62 |
DailyMed Link: | MPI INDIUM DTPA IN 111 at DailyMed |
Recent Clinical Trials for MPI INDIUM DTPA IN 111
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Instituto Nacional de Cancer, Brazil | Phase 1 |
Gary Archer Ph.D. | Phase 2 |
Tomopath Inc. | Early Phase 1 |
US Patents and Regulatory Information for MPI INDIUM DTPA IN 111
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ge Healthcare | MPI INDIUM DTPA IN 111 | indium in-111 pentetate disodium | INJECTABLE;INTRATHECAL | 017707-001 | Feb 18, 1982 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |